Invivyd IVVD 深 沪
已收盘 07-02 16:00:00 美东时间
0.8938
+0.039
+4.61%
华盛通- 最 高0.9068
- 今 开0.8394
- 成交量 220.30万股
- 最 低 0.8394
- 昨 收 0.8544
- 总市值 2.63亿
- 52周最高 3.0699
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 0.483
- 委 比 83.27%
- 总股本 2.95亿
- 历史最高 78.82
- 量 比 0.27
- 振 幅 7.89%
- 历史最低 0.3546
- 每 手 1
- 风险率 0.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
NovaBridge Biosciences announced the appointment of Dr. Srishti Gupta as CEO, effective July 1, 2026, succeeding Dr. Xi-Yong Fu, who will transition to an advisory role. Dr. Gupta, with over two decades of leadership in biopharmaceuticals and global health, aims to advance NovaBridge's innovative medicines, including givastomig and VIS-101, toward registration and establish strategic partnerships. NovaBridge focuses on addressing significant unme...
06-29 11:00
Invivyd Completes Enrollment Phase 3 LIBERTY Trial Of Covid-19 Monoclonal Antibody VYD2311 With An mRNA Covid-19 Vaccine, Topline Data Expected in Q3 2026
Data from LIBERTY can provide important insight into the VYD2311 clinical profile by direct comparison between COVID antibody prophylaxis and COVID vaccine. LIBERTY is part of Invivyd's broader REVOLUTION clinical program, including DECLARATION, designed to generate medical practice-changing data to...
06-16 19:14
美股大行评级 | 大摩再上调希捷科技和西部数据目标价；多家大行首予Lincoln买入评级
今日重点评级关注：HC Wainwright & Co.：维持Elicio Therapeutics"买入"评级，目标价从17美元升至23美元；Leerink Partners：维持SAB Biotherapeutics"跑赢大市"评级，目标价从7美元升至12美元
06-16 11:34
Invivyd Dosed The First Participants In LIBERTY Phase 3 Trial Of VYD2311 Alone, And VYD2311 Co-administered With A Covid-19 Vaccine In Healthy Adults; Topline Data Is Expected In Q3 2026, To Accompany Anticipated Data From Pivotal DECLARATION Study
LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA COVID-19 vaccine, as well as explore the safety and immunology of co-administered VYD2311 and mRNA COVID-19
06-09 19:06
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration
Invivyd, Inc. has initiated the LIBERTY Phase 3 clinical trial to evaluate the safety, tolerability, and immunology of VYD2311, a monoclonal antibody (mAb) candidate, compared to an mRNA COVID-19 vaccine, as well as their co-administration in healthy adults. The trial aims to provide data on the comparative safety profiles and potential benefits of mAb-mediated prophylaxis over traditional vaccines. Topline results are expected in Q3 2026, alongs...
06-09 11:01
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd, Inc. granted 17 new non-executive employees options to purchase 513,500 shares of its common stock on June 1, 2026, under the 2026 Inducement Plan. The options have an exercise price of $1.22 per share, vest over four years, and expire after 10 years. Invivyd is a biopharmaceutical company focused on developing antibodies to combat serious viral diseases, including SARS-CoV-2.
06-03 11:01
Invivyd Completes Enrollment In DECLARATION Phase 3 Trial of VYD2311 To Prevent Symptomatic Covid-19; Top-line Data Expected In Approximately Late Q3 2026
DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of symptomatic COVID-19 versus placebo, at three months, from a single
06-01 19:08
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
Invivyd, Inc. has completed enrollment in the DECLARATION trial evaluating VYD2311, a monoclonal antibody candidate for preventing symptomatic COVID-19. The Phase 3, randomized, placebo-controlled trial assesses the safety and efficacy of a single or monthly intramuscular dose of VYD2311. Enrollment was increased by ~500 participants to enhance statistical power, with top-line results expected by late Q3 2026. The trial aims to provide data suppo...
06-01 11:01
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
BTIG Reiterates Buy on Invivyd, Maintains $10 Price Target
BTIG analyst Thomas Shrader reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $10 price target.
05-18 17:55
